How Will an Appeals Court Ruling on Ruzurgi Affect My Daughter?
Most of us in the Lambert-Eaton myasthenic syndrome (LEMS) community have been following a court case involving Ruzurgi (amifampridine), the only LEMS treatment approved by the U.S. Food and Drug Administration for children under 17. In 2019, Catalyst Pharmaceuticals sued the FDA and other parties over the agency’s…